Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery
Status:
Completed
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
The investigators prepared a novel study of tranexamic acid (TXA) designed to estimate the
quantity of blood loss in women undergoing elective repeat cesarean deliveries. This is the
first trial to utilize a prophylactic dose of TXA prior to incision followed by a subsequent
prophylactic dose at placental delivery in obstetric patients undergoing scheduled cesareans.
The purpose of this study is to quantify blood loss during uncomplicated repeat cesarean
deliveries with and without TXA. The central hypothesis is that TXA administration reduces
blood loss and fibrinolysis in women undergoing repeat cesarean sections.